Cosmo's Male Hair Loss Treatment Delivers Sustained Growth Over Time

Cosmo Pharmaceuticals has reported encouraging results for its male hair loss treatment, clascoterone, showing sustained hair growth over a full year in its latest clinical study released today.

The topical therapy, aimed at treating androgenetic alopecia, demonstrated that continued use leads to stronger and longer-lasting results compared to shorter treatment periods.

According to the company, patients who applied the treatment for 12 months experienced significantly higher hair growth than those who stopped after six months.

The data showed a 2.39 times greater improvement in hair count among long-term users, reinforcing the need for consistent use to maintain visible results. Participants who discontinued early saw a decline in hair density, indicating that stopping treatment reverses progress.

Also Read: Consumer Trust in OTC Products: The Science Behind Safety

Clascoterone works differently from traditional therapies. Instead of affecting hormones throughout the body, it targets androgen receptors directly in the scalp. This localized action reduces the impact of hormones linked to hair follicle shrinkage, a key cause of male pattern baldness. Because of this targeted approach, the treatment showed no major systemic side effects in the study, which adds to its appeal.

Cosmo Pharmaceuticals highlighted that this male hair loss treatment represents a new approach in a space that has seen limited innovation over the past few decades. Existing options often come with side effects or inconsistent results, making new alternatives important for patients seeking safer and more effective solutions.

The company plans to move forward with regulatory submissions, with potential approval expected in the coming years. While the treatment is not yet available on the market, the latest findings position clascoterone as a promising contender in the future of hair loss therapy.